Since 1998, OCRA has awarded 349 grants and invested over $100 million in ovarian cancer research from top scientists at 79 leading medical centers. We invest our dollars wisely, supporting the best ovarian cancer research in the nation.
OCRA-funded projects have led to significant advances in such areas as early detection, diagnosis, genetics, prevention, treatments, and enhancing quality of life.
In just the past year, OCRA-funded researchers have:
- revealed two cells of origin for high-grade serous ovarian cancer — the most common type of ovarian cancer
- defined a combination therapy that significantly delays tumor growth and has implications for improving patient response to immunotherapy
- advanced the design of drug therapy combinations to more effectively kill cancer cells while sparing healthy ones
- identified a new drug that destroys stem-like cancer cells, opening the door to better preventing recurrence
The results of OCRA-supported research projects have been published in some of the world’s most prestigious journals, such as: Gynecologic Oncology, Lancet Oncology, New England Journal of Medicine, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Science Translational Medicine, Cancer Discovery and Nature.